WHO selects Biological E as mRNA technology recipient from WHO technology transfer hub
WHO and partners will work with the Indian government and Bio E to develop a roadmap and put in place the necessary training and support so that the company can start producing mRNA vaccines as soon as possible
The World Health Organization’s (WHO) Product Development for Vaccines Advisory Committee (PDVAC) yesterday selected Biological E (Bio E) as a recipient of mRNA technology from the WHO technology transfer hub, after reviewing a number of proposals from India, a statement from WHO notified.
WHO and partners will work with the Indian government and Bio E to develop a roadmap and put in place the necessary training and support so that the company can start producing mRNA vaccines as soon as possible, the statement said.
Bio E already manufactures a number of critical vaccines, including Corbevax, a second-generation vaccine for COVID-19, it added.
Primarily set up to address the COVID-19 emergency, the hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer, the statement concluded.
- Advertisement -